Clinical usefulness and false-positive results of CA 125 as a tumor marker of ovarian cancer —A study on 674 patients—

K. Takahashi, Kentaro Takahashi, Takahashi K, T Shibukawa, Toshihiko Shibukawa, Shibukawa T, Masashi Moriyama, Moriyama M, M Moriyama, T Shirai, Shirai T, Takaaki Shirai, S Kijima, Kijima S, Satoshi Kijima, Osamu Iwanari, Iwanari O, O Iwanari, Matsunaga I, Isao Matsunaga, I. MATSUNAGA, Kitao M, M Kitao, Manabu Kitao
The Japanese journal of surgery · 1986 · vol. 16(5) , pp. 305–310 · doi:10.1007/bf02470551 · PMID:3467109 · W2082283975
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-08, 2026-08-01 ⓘ

CA 125 serum levels above 34 U/ml were positive in 81.3% of ovarian cancer patients but also in various non-ovarian cancer conditions, suggesting its utility for differentiating benign from malignant ovarian tumors with careful consideration of false positives.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

To study the clinical usefulness and false-positive results of CA 125 as a tumor marker of ovarian cancer, we measured serum CA 125 levels in 197 patients with gynecological diseases, 274 normal, pregnant and postpartum women, 14 patients with abnormal pregnancy, 82 healthy women with a normal ovulatory menstrual cycle and 107 healthy non-pregnant subjects, using RIA kits. A level below 34 U/ml was considered the normal CA 125 range. The positive ratio of serum CA 125 in patients with malignant ovarian tumor was 81.3 per cent, and in those with serous cystadenocarcinoma the rate was 100 per cent. On the other hand, only one patient with benign ovarian tumor had a positive CA 125 value. Therefore, we suggest that CA 125 is useful for differentiation between benign ovarian tumor and ovarian cancer. However, because the positive ratio of CA 125 level is high in patients with recurrences of uterine cervical adenocarcinoma, those with tubal cancer, endometriosis, early pregnancy, abnormal pregnancy plus intrauterine fetal death and menstruating women, such situations must be given due attention when CA 125 is used as a tumor marker of ovarian cancer.

My notes (saved in your browser only)

MeSH descriptors

Antigens, Neoplasm Cystadenocarcinoma Genital Diseases, Female Ovarian Neoplasms Antigens, Neoplasm Antigens, Tumor-Associated, Carbohydrate Cystadenocarcinoma Cystadenocarcinoma Diagnosis, Differential False Positive Reactions Female Genital Diseases, Female Genital Diseases, Female Humans Ovarian Neoplasms Ovarian Neoplasms Pregnancy Pregnancy Complications Pregnancy Complications Radioimmunoassay

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

Cited by (2)

References (10)

Cited by (2)

Source provenance

europepmc
last seen: 2026-08-07T06:07:27.085738+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:09:35.489789+00:00
License: CC0 · commercial use OK